Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
about
Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adultsA phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerOral targeted therapy for cancerCross talk of tyrosine kinases with the DNA damage signaling pathwaysRole of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyNSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesisBreast cancer chemoprevention: old and new approachesPrecision targeted therapy of ovarian cancerInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsHypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural AnalysesBarrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer.A spatial simulation approach to account for protein structure when identifying non-random somatic mutationsVEGF and FGF prime vascular tube morphogenesis and sprouting directed by hematopoietic stem cell cytokines.S100P: a novel therapeutic target for cancer.Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer TherapyA phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Targeted therapies for gastric cancer: current status.A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibitionPhase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.Fusion of nonclinical and clinical data to predict human drug safety.Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsDetection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging.Differential transformation capacity of Src family kinases during the initiation of prostate cancer.Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes.The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.Ectokinases as novel cancer markers and drug targets in cancer therapy.Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionAutophagy protects against dasatinib-induced hepatotoxicity via p38 signaling.Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.Leveraging protein quaternary structure to identify oncogenic driver mutations.MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma.Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III
P2860
Q24187730-23BFFA27-15C9-478F-B08A-CB7A9CF066ECQ24626194-5CDB3BF5-A13E-4937-9CAA-9065A366F9FBQ26773240-F96AD3E2-17FD-4767-BDE1-E7D066CCECF9Q26778614-B947FE8D-CD71-4E08-9E92-790542F76D36Q27026858-E7670F6F-EA57-4BC1-84FB-D9457625C703Q27320669-BF11904E-0344-4430-B412-FFD4099617DEQ27693259-E19994C7-6F9B-4148-A66E-EF497D7CDF1CQ28078658-42BA802C-48B5-490B-BDE9-D13305C8E1D7Q28239708-454315FA-4F6B-4CA7-AEAF-CE3E7F54D94FQ28552577-9660FCC9-1EE7-4CD0-844F-0BC47D92F629Q30317153-20419129-D3B8-4C73-84DF-DF21BE35373AQ30364303-0CDFD5F3-286A-40E4-B690-5C2F436431E9Q30499894-6D2EC373-476E-4B49-813D-059342E7DC8DQ33699305-1C8A9739-7DE8-49E5-8D5C-B2B4086C7EBAQ33862425-74ECD0C2-F877-4169-958D-CB673BC5B97AQ34180815-C2E80ECE-662E-4959-9A73-5A8306DB53CFQ34205672-6886C533-4A96-44AD-BFD4-8773D0422701Q34225395-179E6480-1446-45AB-AFE2-EE174B522200Q34250187-98AD38AF-0E54-450B-9119-DB2C26D90DE9Q34257497-9CB184C6-3F55-4990-9198-6717AD679BC9Q34292469-B539A0FC-E73A-4E1F-809D-55704723B0ADQ34615323-90E660D6-8E07-4A18-9B44-C28A97F64E61Q34714353-917730D0-9A96-413A-B3AA-9885F0E6E28FQ34809415-95B4C4A2-26C3-4EA4-B01B-E4C323F4A0E5Q34835580-63DD3B42-9290-4100-A7A6-4FA9C5829F85Q34996212-BB30C4E9-0226-4300-B6BC-B42F119C05ACQ35232168-83ED9FCC-3631-41D6-8A3F-A0A7B5571CDDQ35236798-C4FAD4B2-7B78-4730-A2BB-03C9951F3795Q35329233-8CD3B9A3-BAAA-48E9-971D-DDED03A721D0Q35583855-CEA3F350-B288-4DDA-834C-B37CBD933987Q35653271-A14A6DC6-08B4-48D3-B2EB-D46DB83277E1Q35677049-25041047-E410-483C-BEF6-DE7573127ED8Q35708124-A44C68AB-BD84-4035-A003-8035C146DEB2Q35740334-0BD1B0BC-BEA9-43D1-AC19-BBA67B298E57Q35742505-B23F0440-5460-4F22-B8CD-8DA86A69AA8AQ35753503-04C811D3-F8B2-49FB-BE70-76D3425BB4D0Q35965565-A5FB588C-4A1F-47E3-BDFE-027D21B9F72CQ36044929-77BFF14F-5DF5-479F-865E-F5C2D8683AB1Q36051470-75B998FE-922E-47C1-9EAE-6E1BE9AA5485Q36088178-472C6515-C6E8-4E21-8356-19E1716A3707
P2860
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@ast
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@en
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@nl
type
label
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@ast
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@en
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@nl
prefLabel
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@ast
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@en
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@nl
P2093
P1476
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
@en
P2093
Hans-Georg Kopp
Jörg Thomas Hartmann
Michael Haap
P304
P356
10.2174/138920009788897975
P407
P577
2009-06-01T00:00:00Z